Table 1.
Comparison of the clinical characteristics and laboratory data among the transgender men group and cisgender control groups, matched for age and body mass index
| Variable | Groups | P value | |||||
|---|---|---|---|---|---|---|---|
| Transgender men | Cisgender women | Cisgender men | |||||
| Mean ± SD | Median (variation) | Mean ± SD | Median (variation) | Mean ± SD | Median (variation) | ||
| Age (yrs)a | 43.6 ± 9.5 | 44 (26-61) |
43 ± 10 | 43.5 (25-61) |
42 ± 10 | 43 (25-61) |
NS |
| BMI (kg/m²)a | 27 ± 5 | 25.9 (19.1-39.2) |
27 ± 5 | 25.4 (19.9-37.1) |
27 ± 4 | — | NS |
| SBP (mmHg)a | 129 ± 17 | 130 (90-180) |
118 ± 15 | 115 (90-160) |
121 ± 17 | 120 (85-180) |
.01* |
| DBP (mmHg) | 81 ± 11 | — | 74 ± 11 | — | 75 ± 14 | — | .02* |
| PP (mmHg) | 47 ± 11 | — | 44 ± 9 | — | 46 ± 11 | — | NS |
| Hematocrit (%) | 47 ± 3 | — | 40 ± 3 | — | 45 ± 2 | — | <.01* |
| TC (mg/dL) | 205 ± 41 | — | 200 ± 36 | — | 190 ± 36 | — | NS |
| HDL-c (mg/dL)a | 47 ± 15 | 46 (29-112) |
50 ± 11 | 48 (29-150) |
43 ± 9 | 41 (27-70) |
.04* |
| LDL-c (mg/dL) | 131 ± 32 | — | 129 ± 30 | — | 119 ± 31 | — | NS |
| Triglycerides (mg/dL)a | 145 ± 92 | 147 (41-540) |
115 ± 74 | 86 (42-346) |
135 ± 75 | 111 (40-425) |
NS |
| FPG (mg/dL)a | 89 ± 14 | 87 (59-128) |
94 ± 9 | 92 (77-113) |
94 ± 9 | 92 (77-113) |
NS |
| Creatinine (mg/dL) | 0.94 ± 0.16 | — | 0.79 ± 0.12 | — | 0.97 ± 0.12 | — | <.01* |
| Testosterone (ng/dL) | 456 ± 250 | — | 36 ± 12 | — | 514 ± 300 | — | <.01* |
| Estradiol (pg/mL) | 38 ± 34 | — | 40 ± 30 | — | 34 ± 26 | — | NS |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NS, nonsignificant; PP, pulse pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; Yrs, years. Unit conversion: testosterone—1 ng/mL = 2.76 nmol/L.
*
P < .05 was considered to be statistically relevant.
a
Nonparametric Kruskal–Wallis test.